HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Calls For Triclosan Ban, Approval Redo, Following FDA, EPA Response

This article was originally published in The Tan Sheet

Executive Summary

Rep. Ed Markey wants to ban many personal care applications of the antimicrobial triclosan and is crafting legislation to authorize government to remove potentially dangerous ingredients from the market more quickly

You may also be interested in...

FDA Should Ban Triclosan, House Democrats Urge

More Democratic House members are calling for a ban on triclosan use in personal-care products with a letter to FDA Commissioner Margaret Hamburg.

Cosmetic Industry Panel's 2010 Priorities Include Triclosan, Talc

A cosmetic industry group's research panel set 17 priorities in the 300 ingredients it plans to evaluate in 2010 - including triclosan, used in antibacterial products and toothpastes and the subject of enduring controversy

Triclosan Concern In Congress Spurs Call For Final Antimicrobial Monograph

Concern about the safety of triclosan prompts a lawmaker to pressure FDA to finalize the OTC Topical Antimicrobial Drug monograph, first proposed in 1972





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts